Funding from the drug industry has paid for quick reviews and more approvals by the FDA. Current law, which limits access to taxpayer dollars, is set to expire in September and would leave the agency without primary funding to carry out drug approval and long-term safety monitoring.

Full Story:
The Seattle Times

Related Summaries